Celgene’s Abraxane rejected on cost groundsAbraxane has been rejected by NICE for use in previously untreated metastatic pancreatic cancer. England’s cost effectiveness watchdog Share XCelgene’s Abraxane rejected on cost groundshttps://pharmaphorum.com/news/celgenes-abraxane-rejected-on-cost-grounds/
BMS sues Merck over cancer immunotherapy patentThe battle for supremacy in the field of anti-PD-1 cancer immunotherapy has just intensified, with Bristol Myers Squibb Share XBMS sues Merck over cancer immunotherapy patenthttps://pharmaphorum.com/news/bms-sues-merck-over-cancer-immunotherapy-patent/
US cancer sufferers rely on online patient communitiesA high level of engagement with online patient communities has been noted in a recent survey of almost Share XUS cancer sufferers rely on online patient communitieshttps://pharmaphorum.com/news/us-cancer-sufferers-rely-on-online-patient-communities/
Senator to table anti-tax inversion bill this weekUS Senator Chuck Schumer is determined to close the loophole that is allowing corporations to keep assets out Share XSenator to table anti-tax inversion bill this weekhttps://pharmaphorum.com/news/senator-to-table-anti-tax-inversion-bill-this-week/
Astellas files new drug for life-threatening infectionsA new treatment for life-threatening infections most commonly affecting immunocompromised cancer patients has been filed with the FDA. Share XAstellas files new drug for life-threatening infectionshttps://pharmaphorum.com/news/astellas-files-new-drug-for-life-threatening-infections/
Merck wins race to market PD-1 inhibitor in USMerck has gained US FDA accelerated approval for new generation drug Keytruda (pembrolizumab), an immunotherapy treatment for advanced Share XMerck wins race to market PD-1 inhibitor in UShttps://pharmaphorum.com/news/merck-wins-race-to-market-pd-1-inhibitor-in-us/
Ebola death toll passes 1,900 as WHO mulls new therapiesAs the Ebola outbreak shows no signs of abating, the World Health Organization (WHO) has convened a meeting to Share XEbola death toll passes 1,900 as WHO mulls new therapieshttps://pharmaphorum.com/news/ebola-death-toll-passes-1-900-as-who-mulls-new-therapies/
Smartphones and social media to gather drug safety dataSmartphones, apps and social media will be used in a European drive to find new ways of gathering Share XSmartphones and social media to gather drug safety datahttps://pharmaphorum.com/news/smartphones-and-social-media-to-gather-drug-safety-data/
Pfizer to promote Novartis respiratory drugs in UKPfizer has signed a deal which will see it promote two Novartis COPD products in the UK. Ultibro Share XPfizer to promote Novartis respiratory drugs in UKhttps://pharmaphorum.com/news/pfizer-to-promote-novartis-respiratory-drugs-in-uk/
